Drugs / fecal microbiota transplantation
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06451588 | Jun 2024 → May 2025 | ankylosing spondylitis, immune dysregulation, neurodevelopmental defects, and colitis | University Hospital of North Norway | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | fecal microbiota transplantation | “The goal of this randomized double-blind study is to evaluate the efficacy of fecal microbiota transplantation (FMT) in patients with axial SpA with a suboptimal effect of...” NCT06451588 ↗ |
| Known as | FMT | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06451588 ↗ |
| Route | Rectal | “Participants will receive a single treatment in the form of an enema with either donor FMT or placebo at baseline.” NCT06451588 ↗ |